** Shares of vaccine developer HilleVax rise ~14% to $2.13 premarket
** HLVX to lay of about 28 employees, or about 70% of its workforce, to reduce operating costs, co said on Thursday
** Co says remaining team will focus on developing norovirus vaccine candidates, HIL-214 and HIL-216
** Co estimates that it will incur charges associated with the workforce reduction of about $6.1 mln
** As of Dec. 31, 2023, HLVX had 90 full-time employees - SEC filling
** Earlier this year, HLVX laid off about 41 employees
** As of last close, stock has fallen 88.4% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。